Navigation Links
Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
Date:3/26/2009

PRINCETON, N.J., March 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that Dr. Geoffrey M. Nichol, Senior Vice President of Product Development at Medarex presented highlights from key programs in Medarex's oncology portfolio at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference in New York. The archived edition of the presentation webcast is available in the Investor Relations section of the Medarex website at www.medarex.com.

Highlights from Medarex's oncology portfolio included the following:

  • Ipilimumab is a fully human anti-CTLA-4 antibody in development for melanoma, prostate cancer and other cancers. Guidance for the completion of the first-line Phase 3 chemotherapy combination trial in melanoma (study 024) remains unchanged and is expected in late 2009, with overall survival as the primary endpoint under the amended Special Protocol Assessment agreement with the U.S. Food and Drug Administration. Initiation of the second-line Phase 3 radiotherapy combination trial in prostate cancer remains on track for mid-2009. Additional data, including survival and biomarker analyses from the melanoma Phase 2 program and data from the Phase 2 prostate program, will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in May/June.
  • MDX-1105 and MDX-1106 are two fully human antibodies that target the PD-L1/PD-1 pathway for the treatment of cancer. MDX-1105 is in an ongoing multi-dose Phase 1 trial for advanced or recurrent renal cancer, melanoma, non-small cell lung cancer or epithelial cancer. MDX-1106 is in an ongoing multi-dose Phase 1b trial for prostate cancer, melanoma, non-small cell lung cancer and renal cancer. Complete MDX-1106 Phase 1 data will
    '/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medarex Announces 2008 Fourth Quarter and Year End Financial Results
2. Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
3. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
4. Medarex Reviews Recent Highlights and Outlook for 2009
5. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
6. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
7. Medarex Announces 2008 First Quarter Financial Results
8. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
9. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
10. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (HealthDay News) -- Potentially illness-causing E. coli bacteria were ... markets, according to a new study. Researchers checked ... 13 farmers markets in Los Angeles and Orange counties ... almost 150 samples tested, 24 percent were positive for ... to the researchers. Both types of bacteria can ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Dense bunches of ... and cancers, a new study finds. The researchers ... of the colon. The presence of these biofilms may ... a new way to predict a person,s risk for the ... on pond stones, these biofilms may coat the mucus layer ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Older adults who ... and walking ability than people who still have at least ... findings suggest that total tooth loss could provide an early ... older people, the British researchers said. However, the findings ... decline. The study included more than 3,100 participants 60 ...
(Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
Breaking Medicine News(10 mins):Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... based on successful,management of nearly 45,000 cases ... NEWPORT NEWS, Va., June 17 ... organization providing direct,case management services and healthcare ... and chronic diseases each year who are,unable ...
... Ore., June 17 Your 83-year old widowed mother,can no ... facility. But she is in,Florida, and you live in California. ... for a suitable assisted living or nursing,home in a strange ... care facility in the western United States and Florida. Available ...
... to help miilions of children in developing world, ... A new compound that may lead to an inexpensive, ... at the University of Texas Health Science Center at ... for developing countries, where diarrhea is a major cause ...
... , The use of the growth hormone in oral ... the integration between the bone base and the dental implant. ... weeks the wait time to place the crown which replaces ... been the resulto f the research of the doctoral thesis ...
... wait to see a doctor could get a lot longer ... care physicians doesn,t increase soon, according to a new University ... community medicine in the MU School of Medicine, and his ... of up to 44,000 family physicians and general internists in ...
... June 17 Among US primary care physicians,Novartis ... by,Pfizer, Merck, GlaxoSmithKline and Sanofi-Aventis, according to new,research ... spot in Europe,demonstrating a consistent ability to build ... rep relationship scores, it has,greater variability in Europe, ...
Cached Medicine News:Health News:Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance 2Health News:New Resource Available for Families Seeking Quality Care for Aging Parents 2Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:Scientists from Granada drastically reduce the wait time for new teeth implant 2Health News:US could face shortage of 44,000 primary care physicians by 2025 2Health News:US could face shortage of 44,000 primary care physicians by 2025 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 4
(Date:12/19/2014)... -- Since last month,s FBI shutdown of online drug ... leading online black market for illegal drugs - Evolution ... of drugs and other illegal items.  New numbers from ... in lowering the numbers of drugs and illegal items ... August. But some new sites that have emerged as ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3ZEISS confirma su posición en un entorno difícil 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
This one of a kind design also provides full body protection. Split down each side, like a poncho, this apron is simple to put on and take off. Available with an orthopedic wide belt or buckle belt....
... gives you the freedom of ... by distributing 70% of the ... leaving only 30% of the ... Freedom of movement enhanced by ...
A simple, one-piece design eliminates seams that irritate and also extend the life of the collar. Comes with extra long Velcro closure to fit all. Also available with trim. One size fits all. Availab...
The maternity apron is a very critical protection device for the patient and the fetus....
Medicine Products: